Share this video  

ASCO 2023 | MAIN-CAV: maintenance cabozantinib and avelumab in urothelial cancer

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, talks on the trial design of the Phase III MAIN-CAV trial (NCT05092958) of maintenance cabozantinib and avelumab in patients with metastatic urothelial cancer. Based on the JAVELIN Bladder 100 trial (NCT02603432), maintenance avelumab is considered the standard of care in this setting, but responses remain poor in patients with certain metastases. The MAIN-CAV will assess the addition of cabozantinib in patients pre-treated with platinum-based chemotherapy, and overall survival will be the primary objective. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.